Evolus, Inc. (EOLS)
NASDAQ: EOLS · Real-Time Price · USD
6.14
-0.09 (-1.44%)
Oct 10, 2025, 4:00 PM EDT - Market closed
Evolus Revenue
Evolus had revenue of $69.39M in the quarter ending June 30, 2025, with 3.70% growth. This brings the company's revenue in the last twelve months to $277.94M, up 17.15% year-over-year. In the year 2024, Evolus had annual revenue of $266.27M with 31.76% growth.
Revenue (ttm)
$277.94M
Revenue Growth
+17.15%
P/S Ratio
1.41
Revenue / Employee
$837,172
Employees
332
Market Cap
397.17M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 266.27M | 64.19M | 31.76% |
Dec 31, 2023 | 202.09M | 53.47M | 35.98% |
Dec 31, 2022 | 148.62M | 48.94M | 49.10% |
Dec 31, 2021 | 99.67M | 43.13M | 76.29% |
Dec 31, 2020 | 56.54M | 21.62M | 61.89% |
Dec 31, 2019 | 34.93M | - | - |
Dec 31, 2018 | - | - | - |
Dec 31, 2017 | - | - | - |
Dec 31, 2016 | - | - | - |
Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
EOLS News
- 1 day ago - Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 19 days ago - Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch - PRNewsWire
- 4 weeks ago - Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer - Business Wire
- 6 weeks ago - Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp - Business Wire
- 7 weeks ago - Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product - Business Wire
- 2 months ago - Evolus, Inc. (EOLS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates - Business Wire